6919:TWSECaliway Biopharmaceuticals Co Ltd Analysis

Technical outlook: The 20‑day SMA (153.2) sits just below the 50‑day SMA (156.1) and both are above the 200‑day SMA (148.4), indicating a neutral price stance. Momentum is modestly bearish with an RSI of 34.6 and a MACD histogram still in negative territory, while the market price of TWD 131 hovers near the identified support level of 128.
Fundamental backdrop: Revenue is growing fast (32.5% YoY) but margins are deeply negative, with operating margin at –9.7% and a trailing EPS of –0.31. Cash balances are healthy (≈TWD 4.86 bn) against minimal debt, yet operating and free cash flow are strongly negative, reflecting ongoing R&D burn. Forward EPS of 5.37 yields a forward P/E of ~24, but the current P/B of 21.6 and price‑to‑sales above 5,000 suggest the stock is priced for strong future success that has yet to materialize. The “Extreme Greed” sentiment index (78.16) and an upside potential of ~83% add optimism, but high 30‑day volatility (≈60%) and a beta under 0.5 highlight a swing‑prone profile.